• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经鼻腔内接种冷适应减毒活 SARS-CoV-2 候选疫苗可预防 SARS-CoV-2。

Intranasal administration of cold-adapted live-attenuated SARS-CoV-2 candidate vaccine confers protection against SARS-CoV-2.

机构信息

Amirabad Virology Laboratory, Vaccine Unit, Tehran 1413693341, Iran.

Department of Microbiology, Faculty Science, Jahrom Branch, Islamic Azad University, Jahrom, Iran.

出版信息

Virus Res. 2022 Oct 2;319:198857. doi: 10.1016/j.virusres.2022.198857. Epub 2022 Jul 9.

DOI:10.1016/j.virusres.2022.198857
PMID:35820511
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9270963/
Abstract

With the COVID-19 pandemic globally, the ongoing threat of new challenges of mucosal infections was once again reminded human beings. Hence, access to the next-generation vaccine to elicit mucosal immunity is required to reduce virus shedding. SARS-CoV-2 retains a unique polybasic cleavage motif in its spike protein, recognized by the host furin protease. The proteolytic furin cleavage site at the junction of S1/S2 glycoprotein plays a key role in the pathogenesis of SARS-CoV-2. Here, we examined the protective immunity of a double-deleted PRRA/GTNGTKR motifs cold-adapted live-attenuated candidate vaccines as a called "KaraVac." using a hamster animal model of infected attenuated SARS-CoV-2. The KaraVac vaccinated hamsters were challenged against the wild-type (WT) SARS-CoV-2. No apparent bodyweight loss and histopathological lesions were observed in the hamsters. The establishment of sterilizing immunity was induced via stimulating a robust neutralizing antibody (NAb) response in a hamster model. Consequently, deletions in the spike sequence and inoculation into hamsters provide resistance to the subsequent challenge with WT SARS-CoV-2. We have suggested that deletion of the furin cleavage site and GTNGTKR motifs in the spike sequence attenuates the virus from the parental strain and can be used as a potent immunogen.

摘要

随着 COVID-19 大流行在全球范围内的肆虐,人们再次意识到新的粘膜感染挑战仍在持续。因此,需要获得新一代疫苗来引发粘膜免疫,以减少病毒脱落。SARS-CoV-2 在其刺突蛋白中保留了一个独特的多碱性切割基序,被宿主弗林蛋白酶识别。S1/S2 糖蛋白交界处的蛋白水解弗林切割位点在 SARS-CoV-2 的发病机制中起着关键作用。在这里,我们使用感染性减弱的 SARS-CoV-2 仓鼠动物模型,研究了一种称为“KaraVac”的双缺失 PRRA/GTNGTKR 基序冷适应活减毒候选疫苗的保护免疫作用。KaraVac 接种的仓鼠在受到野生型(WT)SARS-CoV-2 攻击时没有明显的体重减轻和组织病理学损伤。在仓鼠模型中,通过刺激强烈的中和抗体(NAb)反应建立了杀菌免疫。因此,刺突序列中的缺失和接种到仓鼠体内提供了对随后 WT SARS-CoV-2 攻击的抵抗力。我们已经表明,刺突序列中弗林切割位点和 GTNGTKR 基序的缺失使病毒从亲代株减弱,并可用作有效的免疫原。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/c27b59a73e2f/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/3e58b0a39e86/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/711bfb072617/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/9d1060f64679/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/468136dc14d1/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/d7c986e62932/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/ba9ca71b6101/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/5c3e3eec96be/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/af1745d636e2/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/c27b59a73e2f/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/3e58b0a39e86/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/711bfb072617/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/9d1060f64679/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/468136dc14d1/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/d7c986e62932/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/ba9ca71b6101/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/5c3e3eec96be/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/af1745d636e2/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f0c/9270963/c27b59a73e2f/gr8_lrg.jpg

相似文献

1
Intranasal administration of cold-adapted live-attenuated SARS-CoV-2 candidate vaccine confers protection against SARS-CoV-2.经鼻腔内接种冷适应减毒活 SARS-CoV-2 候选疫苗可预防 SARS-CoV-2。
Virus Res. 2022 Oct 2;319:198857. doi: 10.1016/j.virusres.2022.198857. Epub 2022 Jul 9.
2
SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity.SARS-CoV-2 携带 S1/S2 裂解位点突变表现出毒力减弱,并赋予保护性免疫。
mBio. 2021 Aug 31;12(4):e0141521. doi: 10.1128/mBio.01415-21. Epub 2021 Aug 24.
3
Roles of the polybasic furin cleavage site of spike protein in SARS-CoV-2 replication, pathogenesis, and host immune responses and vaccination.刺突蛋白多碱性弗林裂解位点在 SARS-CoV-2 复制、发病机制、宿主免疫反应和疫苗接种中的作用。
J Med Virol. 2022 May;94(5):1815-1820. doi: 10.1002/jmv.27539. Epub 2021 Dec 31.
4
Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals.鼻腔内给予一剂由 NSP16 缺失的 SARS-CoV-2 株衍生的候选减毒活疫苗可在动物中诱导产生性免疫。
Cell Mol Immunol. 2022 May;19(5):588-601. doi: 10.1038/s41423-022-00855-4. Epub 2022 Mar 29.
5
Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy.可扩展的活减 SARS-CoV-2 候选疫苗具有临床前安全性和有效性。
Proc Natl Acad Sci U S A. 2021 Jul 20;118(29). doi: 10.1073/pnas.2102775118.
6
An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.一种基于鼻腔内的 OMV 疫苗可诱导针对 SARS-CoV-2 感染的高黏膜和全身保护免疫。
Front Immunol. 2021 Dec 17;12:781280. doi: 10.3389/fimmu.2021.781280. eCollection 2021.
7
Spread of Gamma (P.1) Sub-Lineages Carrying Spike Mutations Close to the Furin Cleavage Site and Deletions in the N-Terminal Domain Drives Ongoing Transmission of SARS-CoV-2 in Amazonas, Brazil.携带接近弗林裂解位点的刺突突变和 N 端结构域缺失的伽马(P.1)亚谱系的传播推动了巴西亚马逊州 SARS-CoV-2 的持续传播。
Microbiol Spectr. 2022 Feb 23;10(1):e0236621. doi: 10.1128/spectrum.02366-21.
8
The Cold-Adapted, Temperature-Sensitive SARS-CoV-2 Strain TS11 Is Attenuated in Syrian Hamsters and a Candidate Attenuated Vaccine.适应寒冷、温度敏感的 SARS-CoV-2 株 TS11 在叙利亚仓鼠中减毒,是一种候选减毒疫苗。
Viruses. 2022 Dec 29;15(1):95. doi: 10.3390/v15010095.
9
Vero cell-adapted SARS-CoV-2 strain shows increased viral growth through furin-mediated efficient spike cleavage.通过弗林蛋白酶介导的高效刺突裂解,适应vero 细胞的 SARS-CoV-2 毒株显示出增强的病毒生长。
Microbiol Spectr. 2024 Apr 2;12(4):e0285923. doi: 10.1128/spectrum.02859-23. Epub 2024 Feb 28.
10
SARS-CoV-2 Spike Furin Cleavage Site and S2' Basic Residues Modulate the Entry Process in a Host Cell-Dependent Manner.SARS-CoV-2 刺突蛋白的弗林蛋白酶裂解位点和 S2'碱性残基以宿主细胞依赖的方式调节进入过程。
J Virol. 2022 Jul 13;96(13):e0047422. doi: 10.1128/jvi.00474-22. Epub 2022 Jun 9.

引用本文的文献

1
Respiratory delivered vaccines: Current status and perspectives in rational formulation design.呼吸道给药疫苗:合理剂型设计的现状与展望
Acta Pharm Sin B. 2024 Dec;14(12):5132-5160. doi: 10.1016/j.apsb.2024.08.026. Epub 2024 Nov 4.
2
Breaking Latent Infection: How ORF37/38-Deletion Mutants Offer New Hope against EHV-1 Neuropathogenicity.打破潜伏感染:ORF37/38 缺失突变体如何为对抗 EHV-1 神经致病性带来新希望。
Viruses. 2024 Sep 16;16(9):1472. doi: 10.3390/v16091472.
3
Reverse genetics systems for SARS-CoV-2: Development and applications.

本文引用的文献

1
Intranasal COVID-19 vaccines: From bench to bed.鼻内 COVID-19 疫苗:从实验室到临床。
EBioMedicine. 2022 Feb;76:103841. doi: 10.1016/j.ebiom.2022.103841. Epub 2022 Jan 24.
2
Nasally inhaled therapeutics and vaccination for COVID-19: Developments and challenges.用于新型冠状病毒肺炎的鼻腔吸入疗法和疫苗接种:进展与挑战
MedComm (2020). 2021 Dec 14;2(4):569-586. doi: 10.1002/mco2.101. eCollection 2021 Dec.
3
Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS-CoV-2 Natural Infection.
用于 SARS-CoV-2 的反向遗传学系统:开发与应用。
Virol Sin. 2023 Dec;38(6):837-850. doi: 10.1016/j.virs.2023.10.001. Epub 2023 Oct 11.
4
Indirect Dispersion of SARS-CoV-2 Live-Attenuated Vaccine and Its Contribution to Herd Immunity.严重急性呼吸综合征冠状病毒2减毒活疫苗的间接传播及其对群体免疫的贡献。
Vaccines (Basel). 2023 Mar 14;11(3):655. doi: 10.3390/vaccines11030655.
5
Cold-adapted SARS-CoV-2 variants with different temperature sensitivity exhibit an attenuated phenotype and confer protective immunity.具有不同温度敏感性的冷适应 SARS-CoV-2 变体表现出减弱的表型,并赋予保护性免疫。
Vaccine. 2023 Jan 23;41(4):892-902. doi: 10.1016/j.vaccine.2022.12.019. Epub 2022 Dec 13.
与SARS-CoV-2自然感染相比,mRNA BNT162b2新冠疫苗引发的鼻腔和唾液粘膜体液免疫反应
Vaccines (Basel). 2021 Dec 18;9(12):1499. doi: 10.3390/vaccines9121499.
4
Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA.鼻内预刺激诱导局部肺驻留 B 细胞群体分泌保护性黏膜抗病毒 IgA。
Sci Immunol. 2021 Dec 10;6(66):eabj5129. doi: 10.1126/sciimmunol.abj5129.
5
Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白的突变:对免疫逃逸和疫苗诱导免疫的影响。
Semin Immunol. 2021 Jun;55:101533. doi: 10.1016/j.smim.2021.101533. Epub 2021 Nov 20.
6
The Emergence of the Spike Furin Cleavage Site in SARS-CoV-2.刺突蛋白酶切割位点在 SARS-CoV-2 中的出现。
Mol Biol Evol. 2022 Jan 7;39(1). doi: 10.1093/molbev/msab327.
7
The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.新型冠状病毒(SARS-CoV-2)疫苗的黏膜和血清免疫应答。
Front Immunol. 2021 Oct 12;12:744887. doi: 10.3389/fimmu.2021.744887. eCollection 2021.
8
Safety and potency of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: A preclinical study.用于 SARS-CoV-2 的 BIV1-CovIran 灭活候选疫苗的安全性和效力:一项临床前研究。
Rev Med Virol. 2022 May;32(3):e2305. doi: 10.1002/rmv.2305. Epub 2021 Oct 26.
9
Should the world collaborate imminently to develop neglected live-attenuated vaccines for COVID-19?全球是否应立即合作开发针对 COVID-19 的被忽视的减毒活疫苗?
J Med Virol. 2022 Jan;94(1):82-87. doi: 10.1002/jmv.27335. Epub 2021 Sep 21.
10
Could live attenuated vaccines better control COVID-19?活疫苗能否更好地控制 COVID-19?
Vaccine. 2021 Sep 15;39(39):5719-5726. doi: 10.1016/j.vaccine.2021.08.018. Epub 2021 Aug 11.